Funding to Strengthen KÄÄPÄ Biotech’s Position as a Global Category Leader in Functional Mushroom Ingredients
Karjalohja, Finland, 13.11.2025 - KÄÄPÄ Biotech, a biotechnology company specialised in researching, innovating, developing, producing and selling functional mushroom products, today announced the successful closing of a €9,000,000 strategic investment. This major milestone underscores the company’s market leading position and highlights the ambitious growth plans in the global nutraceutical market.
The funding round was led by PeakBridge, a distinguished global agri-food tech fund manager and member of the Edmond de Rothschild Private Equity partnership, together with Zintinus, a Food Tech sector venture capital fund, aligned with KÄÄPÄ Biotech’s vision for driving innovation in health and wellness sectors.
This strategic investment will accelerate KÄÄPÄ Biotech’s mission to bring premium, traceable, and clinically validated NordRelease® functional mushroom ingredients to the forefront of global wellness and health. The funding will enable the company to increase production capacity, expand vertical integration, scale operations, and strengthen the position of its NordRelease® ingredients as a leader in the global nutraceutical market, and meet the surging demand from international customers across wellness, nutrition, and supplement sectors.
Eric Puro, CEO and Co-Founder of KÄÄPÄ Biotech, commented:
“The functional mushroom market continues to expand rapidly, with the sector fueled by increasing customer demand for high-quality, trustworthy, and science-backed functional mushroom products. We are honored that more than 180 companies across over 20 markets trust us as their preferred partner.
“This strategic investment from both PeakBridge and Zintinus represents a strong vote of confidence in our vision, technology, and team. We are overjoyed by the strengthening relationship with PeakBridge, who invested in us earlier this year. In addition to the strategic partnership and funding, PeakBridge’s tailored value-add programmes for portfolio companies are a cornerstone of their partnership approach, guided by a team with deep food industry expertise. We are equally grateful for the valuable funding, strategic connections, and industry expertise that Zintinus contributes to our ongoing growth. This investment marks a major milestone as we continue scaling our operations to meet global demand while leading innovation in mushroom biotech.”
Dr. Gali Artzi, Partner & CTO at PeakBridge, commented:
"KÄÄPÄ Biotech exemplifies what we look for in this space: vertical integration that addresses real supply chain vulnerabilities, rigorous bioactive standardisation, and a European base that cuts dependence on Asia's concentrated production. Functional mushrooms represent more than a wellness trend; they're a convergence of centuries of traditional use, growing clinical evidence, and modern extraction science that delivers measurable health benefits. KÄÄPÄ is a true sector leader and we're thrilled to expand our support into this next chapter."
Christian Neuss, Partner at Zintinus, commented:
"We are pleased to support KÄÄPÄ Biotech at a pivotal moment for the functional mushroom industry, which is projected to grow rapidly as global demand for science-backed, high-quality functional foods and beverages continues to rise. Through its proprietary NordRelease® extraction process, clinically validated functional mushroom ingredients, and scalable indoor cultivation, KÄÄPÄ Biotech is defining the future of this market, and continues to lead its evolution. Their commitment to transparent production and vertical integration aligns closely with Zintinus’ mission to support transformative food technologies. This strategic partnership enables us to accelerate their next phase of growth and create long-term value for consumers, the environment, and investors."
As recently as September 2024, KÄÄPÄ Biotech unveiled its state-of-the-art mushroom cultivation facility in Paimio, Finland, a pivotal advancement that markedly expanded both production capacity and R&D capabilities. In addition, in June 2025, the company opened another cultivation facility in Salo, Finland, further strengthening its capacity to meet the rapidly growing global demand for Nordic origin, premium functional mushroom ingredients. Today’s strategic investment underscores and accelerates KÄÄPÄ Biotech’s momentum as it scales to serve the expanding wellness and nutrition markets worldwide.